Abstract
T Maher reports that he is an investigator in an ongoing phase 2b study from Gilead, grants and personal fees from GSK, grants from Novartis, personal fees from Boehringer Ingelheim,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have